ARCHIVES

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

This article is from The Cancer Letter archive.

Vol. 31 No. 01 | January 7, 2005

Download PDF Visit The Full Archive

Related Articles

NCAB To Hear Reports On Environmental Carcinogenesis, International Research Efforts

June 4, 1976

NCCS Networker Volume 3 Issue 4, Fall 1989

September 13, 1989

FDA Commissioner Mark McClellan tells NCI audience that science is far from eliminating cancer as a threat.

February 6, 2004

NCI Programs: Contract Awarded For Geographic Information System

May 14, 1999

Outcome Of Prostate Cancer Surgery Depends On Experience Of Surgeon

August 31, 2007

Gallo Wins Another, To Share Hammer Prize With Three Japanese

November 30, 1984